Investor presentation for Critical Outcome Technologies (TSXV: COT), highlighting the Company's lead cancer drug candidate and its small molecule profiling and investment due diligence tool, CHEMFirm.

1. Investor Presentation | May 2014
The future of drug discovery has arrived
Reducing development time, cost & risk

2. 2TSXV: COT
When used anywhere in this presentation, whether oral or written, the words expects,
believes, anticipates, estimates, and similar expressions are intended to identify forward-
looking statements. Forward-looking statements may include statements addressing future
financial and operating results of Critical Outcome Technologies Inc. (COTI).
COTI bases these forward-looking statements on its current expectations about future
events. Such statements are subject to risks and uncertainties including, but not limited to,
the successful implementation of COTI’s strategic plans, the acceptance of new products,
the obsolescence of existing products, the resolution of potential patent issues,
competition, changes in economic conditions, and other risks described in COTI’s public
documents such as press releases and filings with the Toronto Stock Exchange and the
Ontario Securities Commission.
All forward-looking statements are qualified in their entirety by the cautionary statements
included in this document and such filings. These risks and uncertainties could cause actual
results to differ materially from results expressed or implied by forward-looking statements
contained in this presentation. These forward-looking statements speak only as of the date
of this presentation.
Disclaimer

3. 3TSXV: COT
3TSXV: COT
Critical Outcome Technologies Inc.
3
 A bioinformatics
company focused
on efficient and
accelerated drug
discovery
 Listed on the TSX-V
under the symbol COT
since 2006

4. 4TSXV: COT
Investment highlights
1
2
3
We reduce the time, cost & risk of
bringing new drugs to market
Potential cancer breakthrough drug
candidate is nearly Phase 1 ready
We have many more revenue
opportunities in our pipeline

5. 5TSXV: COT
Conventional drug development
is a long & expensive process
characterized by a high risk
of failure
11 – 15
years
$1 billion
or more
1 FDA
approval 5

6. 6TSXV: COT
What we do
 Reduce drug discovery, optimization & lead
selection by 1.5 to 3 yrs.
 Saving significant $$$
 Increasing revenue period under patent
protection

7. 7TSXV: COT
How we do it – CHEMSAS®
7TSXV: COT
Proprietary,
artificial intelligence
based drug
discovery platform
technology

8. 8TSXV: COT
Failed attempts occur
quickly & cheaply in
computer simulations,
not the ‘wet lab’
Higher probability of
clinical & commercial
success
Computational
replication of
traditional
‘wet lab’ drug
discovery process
8
Advantages of CHEMSAS®
TSXV: COT

9. 9TSXV: COT
Potential cancer breakthrough
Our lead compound,
COTI-2, is effective
against many human
cancers with mutations
of the p53 gene

10. 10TSXV: COT
Why COTI-2 is exciting
 > 50% of all human cancers have a p53 mutation
(eg. ~ 95% of serous ovarian cancers)
 Mechanism of action confirmed by thought leader
Dr. Gordon Mills at MD Anderson Cancer Center
(June 2013)
 Novel, first-in-class
 Strong IP protection in place

11. 11TSXV: COT
COTI-2 soon to be Phase 1 ready
 In final 2-species toxicity studies – completion in first half
of 2014 (dosing completed)
 FDA IND filing expected in September of 2014 (leading to
Phase 1 clinical trial)
 Pursuing orphan drug and/or breakthrough therapy status
 Signed an LOI with a potential strategic partner, Portage
Biotech Inc., for clinical development

12. 12TSXV: COTTSXV: COT
COTI-2 = significant revenue potential
 Top 5 2012 Phase 1/2 oncology licensing deals
disclosed (1):
 Upfront payments of approx. $25-$92 million
 Milestone payments between $550-$1,100 million
 Royalties on net sales
 1st half of 2013 (2) – 16 Phase 1 licensing deals with 6
in cancer – avg. upfront $30m
(1) Medius Associates
(2) Thomson Reuters

13. 13TSXV: COT
Other revenue opportunities
 Robust internal pipeline of drug candidates
- AML, MRSA, colorectal and other cancers, MS, etc.
 3 existing R&D collaborations expected to bring in
milestone payments beginning late 2014 / 2015
- Western University
- Delmar Chemicals
- Major Pharma Co.

14. 14TSXV: COTTSXV: COT
 A small molecule profiling & investment due diligence
tool leveraging CHEMSAS®
 Provides detailed report on compound attributes and
specific areas for further assessment
 Identifies properties outside the optimal range that may
represent development challenges
CHEMFirm

15. 15TSXV: COTTSXV: COT
 Enables partners to make more knowledgeable
investment decisions
 Provides critical information for assessing both risk
and value
 Supports a “fail very early & very cheaply” drug
investment strategy
Benefits of CHEMFirm

16. 16TSXV: COT
16TSXV: COT
Other future CHEMSAS® applications
16
 Drug library profiling
Based on customer
identified criteria
 Drug repurposing
Finding new purposes
for drugs coming off
patent

17. 17TSXV: COT
Summary
1
2
3
We reduce the time, cost & risk of
bringing new drugs to market
Potential cancer breakthrough drug
candidate is nearly Phase 1 ready
We have many more revenue
opportunities in our pipeline

18. The future of drug discovery has arrived
Reducing development time, cost & risk
Dr. Wayne Danter
President & CEO
Tel: (519) 858-5157
wdanter@criticaloutcome.com
www.criticaloutcome.com
www.facebook.com/criticaloutcome
twitter.com/criticaloutcome
www.slideshare.net/criticaloutcome